PharmaMar begins PM184 Phase II trial in advanced breast cancer patients

[News]

PharmaMar has announced the start of an open-label multi-centre two-stage Phase II trial with the anti-tumour drug PM184. The trial will be conducted in 10 European clinical centres and will include 106 patients. The trial will focus on patients with hormone-receptor positive, HER2-negative, locally advanced and/or metastatic breast cancer, who have experienced progression following earlier treatment with anthracyclines and taxanes.

More... (http://www.news-medical.net/news/20160226/PharmaMar-begins-PM184-Phase-II-trial-in-advanced-breast-cancer-patients.aspx)